Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.

Circulation. Heart failure - 1 Apr 2018

Rosenblum Hannah, Castano Adam, Alvarez Julissa, Goldsmith Jeff, Helmke Stephen, Maurer Mathew S

Abstract excerpt

BACKGROUND: TTR (transthyretin) cardiac amyloidosis is caused by dissociation of TTR into monomers, which misassemble into amyloid fibrils. TTR stabilizers act at the dimer-dimer interface to prevent dissociation. We investigated differences in survival among patients with TTR cardiac amyloidosis on stabilizer medications compared with those not on stabilizers. METHODS AND RESULTS: A retrospective study of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Amyloid Neuropathies, Familial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Heart Transplantation

Share to Mutation

Share to Prealbumin

Share to Troponin I

Share to Ventricular Function, Left

Source

Open in PubMed Open full text

Identifiers

PMID: 29615436
DOI: 10.1161/CIRCHEARTFAILURE.117.004769
PMCID: PMC5886729

Genes

TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis.PMID 29615436Read ↗

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.Semantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

Transthyretin cardiac amyloidoses in older North Americans.Semantic proximity Read ↗

The transthyretin amyloidoses: advances in therapySemantic proximity Read ↗

From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not 'one-and-done'.Semantic proximity Read ↗

Amyloid and the Heart.Semantic proximity Read ↗

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read ↗

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.